Cash-pretty Australian Biotech Biota Returns $20 Million To Shareholders
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Just days after unveiling positive results from Phase III trials on its second-generation flu treatment laninamivir, co-developed with Daiichi Sankyo, Aussie Biotech Biota announced Aug. 13 that it would issue AU$20 million to its shareholders